Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

On Monday, Ascendis Pharma A/S ASND granted Novo Nordisk A/S NVO an exclusive worldwide license.

The pact will focus on the TransCon technology platform to develop, manufacture, and commercialize Novo Nordisk proprietary products for metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license for cardiovascular diseases.

Also Read: Ascendis Pharma’s Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

The agreement includes provisions requiring certain TransCon technology-based products to be identified and advanced in metabolic diseases to maintain exclusivity in the field and additional provisions for cardiovascular diseases.

Under the terms of the agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas.

The lead program in the collaboration is a once-monthly GLP-1 receptor agonist product candidate that will initially target obesity and type 2 diabetes.

Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program.

In addition, Ascendis will be eligible to receive sales-based milestone payments and tiered royalties on global net sales.

For each additional metabolic or cardiovascular disease product candidate, Ascendis will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.

Ascendis will conduct early development of TransCon product candidates in collaboration.

Novo Nordisk will be responsible for these early development costs, clinical development, regulatory, commercial manufacturing, and commercialization.

“The agreement with Novo Nordisk reflects our Vision 2030 to create value in additional large therapeutic areas outside endocrinology rare disease through collaborations with established global leaders,” said Jan Mikkelsen, Ascendis Pharma’s President and CEO.

“We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases,” said Brian Vandahl, Senior Vice President of Global Research Technologies at Novo Nordisk.

The transaction is expected to close before the end of 2024.

Price Action: At the last check on Monday, ASND stock was up 1.91% at $127.67, and NVO stock was down 1.61% at $110.14.

Read Next:

• TotalEnergies Bolsters LNG Presence In China With 15-Year Supply Deal: Details

Photo by Tobias Arhelger via Shutterstock